Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026Received ...
Cantech Letter

Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

Ferring Pharmaceuticals and Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) are pleased to announce that they have entered into ...

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in ...